Role of Early Versus Late Switch to Lapatinib-Capecitabine
NCT ID: NCT01357863
Last Updated: 2018-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
3 participants
OBSERVATIONAL
2010-07-15
2010-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
NCT01160094
Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
NCT01985893
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
NCT00479856
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
NCT00320385
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
NCT00073528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients on second line treatment
Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
Treatment
Patients treated with Lapatinib-capecitabine after Trastuzumab progression
Patients on third or more lines treatment
Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
Treatment
Patients treated with Lapatinib-capecitabine after Trastuzumab progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment
Patients treated with Lapatinib-capecitabine after Trastuzumab progression
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Vitória, Espírto Santo, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Goiânia, Goiás, Brazil
GSK Investigational Site
Goiânia, Goiás, Brazil
GSK Investigational Site
Natal, Rio Grande do Norte, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Florianópolis, Santa Catarina, Brazil
GSK Investigational Site
São José dos Campos, São Paulo, Brazil
GSK Investigational Site
Belo Horizonte, , Brazil
GSK Investigational Site
Rio de Janeiro, , Brazil
GSK Investigational Site
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
113960
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.